Loading...
Loading...
LUMO| Name | Value |
|---|---|
| Revenues | 512.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 512.0K |
| Operating Expense | 9,347.0K |
| Operating I/L | -8,835.0K |
| Other Income/Expense | 575.0K |
| Interest Income | 503.0K |
| Pretax | -8,260.0K |
| Income Tax Expense | -588.0K |
| Net Income/Loss | -7,672.0K |
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for rare diseases. Their lead therapeutic candidate, LUM-201, is an oral growth hormone secretagogue ibutamoren currently in Phase 2 clinical trial for pediatric growth hormone deficiency and other rare endocrine disorders.
